Details for New Drug Application (NDA): 219042
The generic ingredient in HERNEXEOS is zongertinib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the zongertinib profile page.
Summary for 219042
| Tradename: | HERNEXEOS |
| Applicant: | Boehringer Ingelheim |
| Ingredient: | zongertinib |
| Patents: | 2 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 219042
Generic Entry Date for 219042*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 219042
| Mechanism of Action | Breast Cancer Resistance Protein Inhibitors HER2/Neu/cerbB2 Antagonists |
Suppliers and Packaging for NDA: 219042
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| HERNEXEOS | zongertinib | TABLET;ORAL | 219042 | NDA | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-9257 | 0597-9257-59 | 1 BOTTLE, PLASTIC in 1 CARTON (0597-9257-59) / 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC |
| HERNEXEOS | zongertinib | TABLET;ORAL | 219042 | NDA | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-9257 | 0597-9257-86 | 1 BOTTLE, PLASTIC in 1 CARTON (0597-9257-86) / 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 60MG | ||||
| Approval Date: | Aug 8, 2025 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Aug 8, 2030 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Patent: | 11,608,343 | Patent Expiration: | Jul 21, 2041 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | USE OF ZONGERTINIB FOR TREATING NON-SMALL CELL LUNG CANCER (NSCLC) | ||||||||
| Patent: | 12,171,739 | Patent Expiration: | Nov 15, 2026 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Expired US Patents for NDA 219042
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | HERNEXEOS | zongertinib | TABLET;ORAL | 219042-001 | Aug 8, 2025 | 12,171,739 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
